WallStSmart

Spotify Technology SA (SPOT)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Spotify Technology SA generates 43% more annual revenue ($17.19B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 12.9%. SPOT appears more attractively valued with a PEG of 1.99. VRTX earns a higher WallStSmart Score of 66/100 (B-).

SPOT

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 8.7Quality: 7.5
Piotroski: 4/9Altman Z: 2.66

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SPOTUndervalued (+13.1%)

Margin of Safety

+13.1%

Fair Value

$560.66

Current Price

$473.21

$87.45 discount

UndervaluedFair: $560.66Overvalued
VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SPOT3 strengths · Avg: 9.3/10
Return on EquityProfitability
31.9%10/10

Every $100 of equity generates 32 in profit

Market CapQuality
$99.82B9/10

Large-cap with strong market position

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

SPOT4 concerns · Avg: 3.5/10
PEG RatioValuation
1.994/10

Expensive relative to growth rate

Price/BookValuation
10.1x4/10

Trading at 10.1x book value

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

P/E RatioValuation
40.5x2/10

Premium valuation, high expectations priced in

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : SPOT

The strongest argument for SPOT centers on Return on Equity, Market Cap, Debt/Equity.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : SPOT

The primary concerns for SPOT are PEG Ratio, Price/Book, EPS Growth. A P/E of 40.5x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SPOT profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

SPOT carries more volatility with a beta of 1.72 — expect wider price swings.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

SPOT generates stronger free cash flow (834M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 62/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Spotify Technology SA

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Spotify Technology SA, provides audio streaming services worldwide. The company is headquartered in Luxembourg, Luxembourg.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?